Cargando…

Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care

The available data suggest differences in the course of type 2 diabetes mellitus (T2DM) between men and women, influenced by the distinguishing features of the sex. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a relatively new class of antidiabetic drugs that act by mimicking the functi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rentzeperi, Elpiniki, Pegiou, Stavroula, Koufakis, Theocharis, Grammatiki, Maria, Kotsa, Kalliopi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950819/ https://www.ncbi.nlm.nih.gov/pubmed/35330453 http://dx.doi.org/10.3390/jpm12030454

Ejemplares similares

The role of sexual dimorphism in susceptibility to SARS-CoV-2 infection, disease severity, and mortality: facts, controversies and future perspectives
por: Pegiou, Stavroula, et al.
Publicado: (2021)

How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
por: Arvanitakis, Konstantinos, et al.
Publicado: (2022)

Managing Diabetes in the Era of Financial Crisis: Need to Look Beyond the Obvious
por: Koufakis, Theocharis, et al.
Publicado: (2018)

Changes in the Global Epidemiology of Type 1 Diabetes in an Evolving Landscape of Environmental Factors: Causes, Challenges, and Opportunities
por: Ogrotis, Ioannis, et al.
Publicado: (2023)

The Relationship between Primary Hyperparathyroidism and Thrombotic Events: Report of Three Cases and a Review of Potential Mechanisms
por: Koufakis, Theocharis, et al.
Publicado: (2018)

Epidemiological, Pathophysiological, and Clinical Considerations on the Interplay between Thyroid Disorders and Type 2 Diabetes Mellitus
por: Grigoriadis, Gregory, et al.
Publicado: (2023)

Potential Role of Ultrafast-acting Insulin Analogues in the Treatment of Diabetic Ketoacidosis
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Vitamin D Alleviates Anxiety and Depression in Elderly People with Prediabetes: A Randomized Controlled Study
por: Zaromytidou, Evangelia, et al.
Publicado: (2022)

COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong
por: Koufakis, Theocharis, et al.
Publicado: (2022)

The importance of sleep quality, quantity, and chronotype in the management of diabetes: Is it time to wake up?
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Antiatherosclerotic Effects of Sodium-Glucose Cotransporter 2 Inhibitors: An Underrecognized Piece of the Big Puzzle?
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Deconvoluting the Biological Roles of Vitamin D-Binding Protein During Pregnancy: A Both Clinical and Theoretical Challenge
por: Karras, Spyridon N., et al.
Publicado: (2018)

Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun
por: Karras, Spyridon N, et al.
Publicado: (2019)

Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases
por: Koufakis, Theocharis, et al.
Publicado: (2021)

Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
por: Veneti, Stavroula, et al.
Publicado: (2020)

Looking deeper into the findings of DARE-19: Failure or an open door to future success?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

Changes in dietary intake of aspartic acid during and after intermittent fasting correlate with an improvement in fasting glucose in overweight individuals
por: Karras, Spyridon N., et al.
Publicado: (2023)

Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes
por: Kyriakidou, Artemis, et al.
Publicado: (2022)

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
por: Vasdeki, Dimitra, et al.
Publicado: (2022)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon‐like peptide‐1 receptor agonists
por: Yassine, Hussein N., et al.
Publicado: (2021)

Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study
por: Kolokas, Konstantinos, et al.
Publicado: (2020)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice
por: He, Min, et al.
Publicado: (2010)

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide
por: Pickford, Philip, et al.
Publicado: (2020)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
por: Babenko, Alina Yu., et al.
Publicado: (2019)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
por: Alorfi, Nasser M, et al.
Publicado: (2022)

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
por: Lucey, Maria, et al.
Publicado: (2020)

Effects of Christian Orthodox Fasting Versus Time-Restricted Eating on Plasma Irisin Concentrations Among Overweight Metabolically Healthy Individuals
por: Karras, Spyridon N., et al.
Publicado: (2021)

From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bocmi6vm7e7i58j6l7mv44hn1b